SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
4.640
-0.140 (-2.93%)
At close: Apr 23, 2026, 4:00 PM EDT
4.520
-0.120 (-2.59%)
After-hours: Apr 23, 2026, 7:59 PM EDT
SLS Employees
SELLAS Life Sciences Group had 13 employees as of December 31, 2025. The number of employees decreased by 2 or -13.33% compared to the previous year.
Employees
13
Change (1Y)
-2
Growth (1Y)
-13.33%
Revenue / Employee
n/a
Profits / Employee
-$2,066,385
Market Cap
833.26M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 13 | -2 | -13.33% |
| Dec 31, 2024 | 15 | -1 | -6.25% |
| Dec 31, 2023 | 16 | -1 | -5.88% |
| Dec 31, 2022 | 17 | 6 | 54.55% |
| Dec 31, 2021 | 11 | 4 | 57.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| Kura Oncology | 260 |
| ARS Pharmaceuticals | 163 |
| Solid Biosciences | 121 |
| Cullinan Therapeutics | 109 |
| Theravance Biopharma | 90 |
| Vor Biopharma | 76 |
| Design Therapeutics | 54 |
SLS News
- 27 days ago - These 16 stocks are a short seller's dream — likely losers no matter what the market does - Market Watch
- 5 weeks ago - SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference - GlobeNewsWire
- 6 weeks ago - SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 - GlobeNewsWire
- 7 weeks ago - What's Going With SELLAS Life Sciences Stock On Wednesday? - Benzinga
- 3 months ago - SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe - GlobeNewsWire
- 4 months ago - SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - GlobeNewsWire
- 4 months ago - SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 - GlobeNewsWire